RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
Retrieved on:
Tuesday, November 15, 2022
Diagnosis, PET, Low-density lipoprotein receptor-related protein 8, PDAC, Cancer, Connective tissue, Brain, PET/CT, Patient, Pancreatic cancer, Neoplasm, LDLR, Glioblastoma, Baantjer, de film: De Cock en de wraak zonder einde, CGMP, US, Targeted alpha-particle therapy, GBM, Pancreas, Radiation, CSO, Aix-Marseille University, TAT, Radiopharmaceutical, Investigational New Drug, Quality of life, CNRS, Clinical trial, Traffic barrier, US FDA, Safety, Drug development, Medical imaging
PDAC is one of the most chemo-resistant and radio-resistant types of cancers due to the dense pancreatic connective tissue and the diversity of genetic mutations.
Key Points:
- PDAC is one of the most chemo-resistant and radio-resistant types of cancers due to the dense pancreatic connective tissue and the diversity of genetic mutations.
- Our current therapeutic approaches for these cancers are invasive and fail meaningful results while adversely effects on the quality of life of our patients.
- RadioMedix is serving as a Sponsor and manufacturer of the clinical doses of 68Ga-RMX-VH., said Dr. Izabela Tworowska, CSO of RadioMedix.
- In addressing other unmet needs in oncology, RadioMedix is developing theranostic agents to treat brain tumors, and pancreatic ductal adenocarcinoma (PDAC).